Home>
US Stocks>
Catalyst Pharmaceuticals

Catalyst Pharmaceuticals share price today

(CPRX)

Catalyst Pharmaceuticals share price is $21.27 & ₹1,807.44 as on 21 Dec 2024, 2.30 'hrs' IST

$21.27

▲

-0.19

(-0.89%)

Market is closed - opens 8 PM, 23 Dec 2024

View live Catalyst Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Catalyst Pharmaceuticals from India. Also see the sentimental analysis on Indian investors investing in Catalyst Pharmaceuticals. Get details on the Indian mutual funds that are investing in Catalyst Pharmaceuticals. Get Analyst recommendations and forecasts along with all the Catalyst Pharmaceuticals's financials.

Catalyst Pharmaceuticals share price movements

Today's Low: $21.01
Today's High: $21.34
$21.27
1.22%
Downside
Day's Volatility :1.55%
Upside
0.33%
52 Weeks Low: $13.12
52 Weeks High: $24.27
$21.27
38.34%
Downside
52 Weeks Volatility :45.96%
Upside
12.36%

Catalyst Pharmaceuticals Returns

Period	Catalyst Pharmaceuticals Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	3.81%	-11.1%	0.0%
6 Months	38.21%	-6.0%	0.0%
1 Year	24.1%	2.7%	0.0%
3 Years	196.24%	0.6%	-19.7%

Catalyst Pharmaceuticals Key Statistics

in dollars & INR

Previous Close	$21.46
Open	$21.27
Today's High	$21.34
Today's Low	$21.01
Market Capitalization	$2.6B
Today's Volume	$1.6M
52 Week High	$24.27
52 Week Low	$13.1161
Revenue TTM	$460.5M
EBITDA	$211.4M
Earnings Per Share (EPS)	$1.18
PE Ratio	18.19
Profit Margin	31.01%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	28.29%

How to invest in Catalyst Pharmaceuticals from India?

It is very easy for Indian residents to invest directly in Catalyst Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Catalyst Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Catalyst Pharmaceuticals or CPRX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Catalyst Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Catalyst Pharmaceuticals shares which would translate to 0.040 fractional shares of Catalyst Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Catalyst Pharmaceuticals, in just a few clicks!

Returns in Catalyst Pharmaceuticals for Indian investors in Rupees

Investment Value

₹1,00,000

Catalyst Pharmaceuticals investment value today

Current value as on today

₹1,26,292

Returns

₹26,292

(+26.29%)

Returns from Catalyst Pharmaceuticals Stock

₹24,096 (+24.1%)

Dollar Returns

₹2,196 (+2.2%)

Indian investors sentiment towards Catalyst Pharmaceuticals

83%

Period: Sep 22, 2024 to Dec 21, 2024. Change in 30 Days versus previous period

Search volume for Catalyst Pharmaceuticals on INDmoney from India has grown in the last 30 days as on Dec 22, 2024. 83% more investors are searching Catalyst Pharmaceuticals in the last 30 days versus the previous period.

Global Institutional Holdings in Catalyst Pharmaceuticals

BlackRock Inc
15.67%
Vanguard Group Inc
6.74%
Deerfield Management Co
5.22%
State Street Corp
4.77%
Dimensional Fund Advisors, Inc.
2.53%
Pacer Advisors, INC.
2.35%

Analyst Recommendation on Catalyst Pharmaceuticals

Buy

92%Buy

7%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Catalyst Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Catalyst Pharmaceuticals

What analysts predicted

Upside of 51.62%

Current:

$21.27

Target:

$32.25

Insights on Catalyst Pharmaceuticals

Price Movement
In the last 3 years, CPRX stock has moved up by 208.3%
Increasing Revenue
Revenue is up for the last 3 quarters, 98.50M → 128.69M (in $), with an average increase of 12.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 23.27M → 43.88M (in $), with an average increase of 25.0% per quarter
CPRX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 35.5% return, outperforming this stock by 3.1%
Price to Sales
ForCPRX every $1 of sales, investors are willing to pay $5.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Catalyst Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Catalyst Pharmaceuticals is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Catalyst Pharmaceuticals Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Catalyst Pharmaceuticals Inc	-0.98%	38.21%	24.1%	196.24%	431.75%
Regeneron Pharmaceuticals, Inc.	-5.73%	-34.03%	-17.38%	12.23%	86.41%
Biontech Se	4.48%	30.56%	7.97%	-55.71%	237.85%
Alnylam Pharmaceuticals, Inc.	-0.55%	10.11%	28.37%	26.29%	108.55%
Vertex Pharmaceuticals Incorporated	-11.79%	-16.36%	-2.55%	77.79%	80.12%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Catalyst Pharmaceuticals Inc	18.19	18.19	0.0	2.04	0.28	0.18	NA	5.54
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Catalyst Pharmaceuticals Inc	Buy	$2.6B	431.75%	18.19	31.01%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	86.41%	17.51	33.61%
Biontech Se	Buy	$26.7B	237.85%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	108.55%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.12%	32.84	-4.51%

About Catalyst Pharmaceuticals

catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso

Organization	Catalyst Pharmaceuticals
Employees	167
CEO	Mr. Richard John Daly M.B.A.
Industry	Health Technology

Management People of Catalyst Pharmaceuticals

Name	Title
Mr. Richard John Daly M.B.A.	President, CEO & Director
Dr. Steven R. Miller Ph.D.	Executive VP, COO & Chief Scientific Officer
Dr. Gary Ingenito M.D., Ph.D.	Chief Medical & Regulatory Officer
Mr. Jeffrey Del Carmen	Executive VP & Chief Commercial Officer
Mr. Michael W. Kalb CPA	Executive VP, Treasurer & CFO
Ms. Mary Coleman	VP & Head of Investor Relations
Mr. Brian Elsbernd J.D.	Chief Compliance Officer & Chief Legal Officer
Mr. Pete Curry Sr.	Vice President of Sales
Dr. Stanley Iyadurai M.D., Ph.D.	Senior Vice President of Medical Affairs & Drug Discovery
Dr. Preethi Sundaram Ph.D.	Chief Strategy Officer

Important FAQs about investing in Catalyst Pharmaceuticals from India :

What is Catalyst Pharmaceuticals share price today?

Catalyst Pharmaceuticals share price today stands at $21.27, Open: $21.27 ; Previous Close: $21.46 ; High: $21.34 ; Low: $21.01 ; 52 Week High: $24.27 ; 52 Week Low: $13.12. The stock opens at $21.27, after a previous close of $21.46. The stock reached a daily high of $21.34 and a low of $21.01, with a 52-week high of $24.27 and a 52-week low of $13.12.

Can Indians buy Catalyst Pharmaceuticals shares?

Yes, Indians can invest in the Catalyst Pharmaceuticals (CPRX) from India.

With INDmoney, you can buy Catalyst Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Catalyst Pharmaceuticals at zero transaction cost.

How can I buy Catalyst Pharmaceuticals shares from India?

It is very easy to buy Catalyst Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Catalyst Pharmaceuticals be purchased?

Yes, you can buy fractional shares of Catalyst Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Catalyst Pharmaceuticals stocks?

To start investing in Catalyst Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.